Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Leaderboard Analytics
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Abbott Laboratories Infant Formula Shareholder Derivative Litigation
Case Number:
1:22-cv-05513
Court:
Nature of Suit:
160 Contract: Stockholders Suits
Judge:
Firms
- Bernstein Litowitz
- Cohen Milstein
- Edward T. Joyce & Associates
- Freed Kanner
- Gardy & Notis
- Kirkland & Ellis
- Latham & Watkins
- Lieff Cabraser
- McGuireWoods
- Scott&Scott
- Wolf Haldenstein
- Zwerling Schachter
Companies
- Abbott Laboratories
- International Brotherhood of Teamsters
- KBC Group NV
- Southeastern Pennsylvania Transportation Authority
Sectors & Industries:
-
February 14, 2025
Some Discovery On Hold In Abbott Infant Formula Case
An Illinois federal judge granted in part a request by Abbott Laboratories to pause a shareholder derivative suit over how it managed the 2022 infant formula crisis, allowing written discovery to go on while staying depositions until May.
-
December 05, 2024
Abbott Accused Of 'Last-Ditch Effort' To Halt Formula Suit
Investors accusing Abbott Laboratories leaders of concealing known safety issues related to recalled infant formula urged an Illinois federal judge to reject the company's bid to stay the case because it belatedly formed a special litigation committee to investigate the allegations two years into the litigation.
-
August 07, 2024
Abbott Brass Trim But Can't Nix Investors' Formula Recall Suit
A Chicago federal judge on Wednesday substantially trimmed a derivative suit accusing Abbott Laboratories leaders of concealing known safety issues related to recalled infant formula but rejected the defendants' argument that tossing the suit in its entirety was in shareholders' "best interest."
-
October 11, 2022
Investor Says Abbott Laboratories Hid Formula Plant Woes
An Abbott Laboratories stockholder has launched a derivative suit accusing the company's leadership of misleading investors by hiding what they knew about contamination at one of Abbott's infant formula plants.